Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Wong SW, Bar N, Paris L, Hofmeister CC, Hansson M, Santoro A, Mateos MV, Rodriguez-Otero P, Lund J, Encinas C, Yee AJ, Oriol A, Cerchione C, De La Rubia J, Ferstl B, Carlson K, Ribas P, Bermudez A, Boss IW, Gaudy A, Li S, Hsu K, Godwin CD, Burgess MR, San-Miguel J, Costa LJ (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

Event location: New Orleans, LA

DOI: 10.1182/blood-2022-159009

Involved external institutions

Skåne University Hospital / Skånes universitetssjukhus Sweden (SE) Karolinska University Hospital / Karolinska Universitetssjukhuset Sweden (SE) Marqués de Valdecilla University Hospital / Hospital Universitario de Marqués de Valdecilla (HUMV) Spain (ES) Emory University United States (USA) (US) University of California San Francisco (UCSF) United States (USA) (US) ASST Papa Giovanni XXIII Italy (IT) Uppsala University Hospital / Akademiska sjukhuset Sweden (SE) Istituto Clinico Humanitas Italy (IT) Hospital General Universitario Gregorio Marañón Spain (ES) Massachusetts General Hospital United States (USA) (US) Yale University United States (USA) (US) Clínica Universidad de Navarra Spain (ES) Hospital Universitari Germans Trias i Pujol Spain (ES) University of Salamanca / Universidad de Salamanca Spain (ES) Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) Italy (IT) Hospital Universitario Dr. Peset Aleixandre Spain (ES) Bristol-Myers Squibb United States (USA) (US) University of Alabama in Huntsville (UAH) United States (USA) (US) Hospital Universitario y Politécnico de La Fe Spain (ES)

How to cite

APA:

Wong, S.W., Bar, N., Paris, L., Hofmeister, C.C., Hansson, M., Santoro, A.,... Costa, L.J. (2022). Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study. In BLOOD. New Orleans, LA, US: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Wong, Sandy W., et al. "Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study." Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA WASHINGTON: AMER SOC HEMATOLOGY, 2022.

BibTeX: Download